Role of Avastin in management of central serous chorioretinopathy

Saudi Journal of Ophthalmology

Volumn 24, Issue 3, 2010, Pages 69-75

  Mehany, Shaaban A ^a   Shawkat, Ahmad M ^a   Sayed, Mohamed F ^a   Mourad, Khaled M ^a  

^a MINIA UNIVERSITY HOSPITAL   (Egypt)

Author keywords

Avastin (bevacizumab); Central serous chorioretinopathy; FA; Intravitreal injection; OCT

Indexed keywords

BEVACIZUMAB;

ADULT; ARTICLE; CENTRAL SEROUS RETINOPATHY; CLINICAL ARTICLE; CLINICAL TRIAL; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; FEMALE; FLUORESCENCE ANGIOGRAPHY; FOLLOW UP; HUMAN; INTRAOCULAR PRESSURE; MALE; OPTICAL COHERENCE TOMOGRAPHY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; SUBRETINAL FLUID; SUBRETINAL NEOVASCULARIZATION; TREATMENT RESPONSE; VISUAL ACUITY;

EID: 77952543563     PISSN: 13194534     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.sjopt.2010.03.002     Document Type: Article

References (17)

1. Cardillo Piccolino F., Borgia L., Zinicola E., et al. Indocyanine green angiographic findings in central serous chorioretinopathy. Eye 9 (1995) 324-332
2. Cardillo Piccolino F., Eandi C.M., Ventre L., et al. Photodynamic therapy for chronic central serous chorioretinopathy. Retina 23 (2003) 752-763
3. Carvalho-Recchia C.A., Yannuzzi L.A., Negrao S., et al. Corticosteroids and central serous chorioretinopathy. Ophthalmology 109 10 (2002) 1834-1837
4. Chan W.M., Lam D.S.C., Lai T.Y.Y., et al. Choroidal vascular remodeling in central serous chorioretinopathy after indocyanine green guided photodynamic therapy with verteporfin: a novel treatment at primary disease level. Br. J. Ophthalmol. 87 (2003) 1453-1458
5. Chappelow A.V., and Marmor M.F. Multifocal electroretinogram abnormalities persist following resolution of central serous chorioretinopathy. Arch. Ophthalmol. 118 (2000) 1211-1215
6. Cotticelli L., Borrelli M., D'Alessio A.C., et al. Central serous chorioretinopathy and Helicobacter pylori. Eur. J. Ophthalmol. 16 2 (2006) 274-278
7. El-Batarny A.M., Tamersh M.K., Kabeel M.M., et al. Role of intravitreal bevacizumab (Avastin) in the management of chronic and recurrent central serous chorioretinopathy (CSC). Bull. Ophthalmol. Soc. Egypt. 101 4 (2008) 451-458
8. Jalk A.E., Jabbour N., Avila M.P., et al. Pigment epithelium decompensation, clinical features and natural course. Ophthalmology 91 (1984) 1544-1548
9. Loo R.H., Scott I.U., Flynn Jr. H.W., et al. Factors associated with reduced visual acuity during long-term follow up of patients with idiopathic central serous chorioretinopathy. Retina 22 (2002) 19-24
10. Penha F.M., Aggio F.B., Bonomo P.P., et al. Severe retinal thermal injury after indocyanine green-mediated photothrombosis for central serous chorioretinopathy. Am. J. Ophthalmol. 143 5 (2007) 887-889
11. Schaal K.B., Hoeh A.E., Scheuerle A., Schuett F., Dithmar S., et al. Intravitreal bevacizumab for treatment of chronic central serous chorioretinopathy. Eur. J. Ophthalmol. 19 4 (2009) 613-617
12. Seong K.H., Bae J.H., Kim E.S., et al. Intravitreal bevacizumab to treat acute central serous chorioretinopathy: short-term effect. Ophthalmologica 223 5 (2009) 343-347
13. Shams N., and Ianchulev T. Role of vascular endothelial growth factor in ocular angiogenesis. Ophthalmol. Clin. North Am. 19 3 (2006) 335-344
14. Stewart J.M. Central serous chorioretinopathy half dose verteporfin PDT for central serous chorioretinopathy. Br. J. Ophthalmol. 90 (2006) 805-806 (editrorial)
15. Tewari H.K., Gadia R., Kumar D., Venkatesh P., et al. Sympathetic-parasympathetic activity and reactivity in central serous chorioretinopathy: a case-control study. Invest. Ophthalmol. Vis. Sci. 47 8 (2006) 3474-3478
16. Torres-Soriano M.E., Garcia-Aguirre G., Kon-Jara V., et al. A pilot study of intravitreal bevacizumab for the treatment of central serous chorioretinopathy (case reports). Graefe's Arch. Clin. Exp. Ophthalmol. 246 9 (2008) 1235-1239
17. Wang M., Sander B., and Larsen M. Retinal atrophy in idiopathic central serous chorioretinopathy. Am. J. Ophthalmol. 133 (2002) 787-793